Immunotherapy of cancer in the era of checkpoint inhibitor

被引：0

作者：

Inderjit Mehmi

Omid Hamid

机构：

[1] The Angeles Clinic and Research Institute,

[2] Cedar Sinai Affiliate,undefined

来源：

Clinical & Experimental Metastasis | 2022年 / 39卷

关键词：

Melanoma; cSCC; MCC; Immunotherapy; Checkpoint inhibitors; TIM-3; LAG-3; Cytokines; NSCLC;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

Application of immunotherapy has revolutionized treatment of number of malignancies. We present a review of immunotherapy approaches, early-phase data of number of new immunotherapeutic targets in melanoma, cutaneous squamous cell carcinoma, Merkel cell cancer, and non-small cell lung cancer.

引用

页码：231 / 237

页数：6

共 50 条

[41] Checkpoint inhibitor immunotherapy toxicity and overall survival among older adults with advanced cancer
Johns, Andrew C.
Wei, Lai
Grogan, Madison
Hoyd, Rebecca
Bridges, John F. P.
Patel, Sandipkumar H.
Li, Mingjia
Husain, Marium
Kendra, Kari L.
Otterson, Gregory A.
Burkart, Jarred T.
Rosko, Ashley E.
Andersen, Barbara L.
Carbone, David P.
Owen, Dwight H.
Spakowicz, Daniel J.
Presley, Carolyn J.
JOURNAL OF GERIATRIC ONCOLOGY, 2021, 12 (05) : 813 - 819
[42] Monalizumab Anti-NKG2A monoclonal antibody, Checkpoint inhibitor, Cancer immunotherapy
Gajdosik, Z.
DRUGS OF THE FUTURE, 2019, 44 (09) : 699 - 704
[43] Imaging of Immune Checkpoint Inhibitor Immunotherapy for Non-Small Cell Lung Cancer
Shroff, Girish S.
Strange, Chad D.
Ahuja, Jitesh
Altan, Mehmet
Sheshadri, Ajay
Unlu, Ebru
Truong, Mylene T.
Vlahos, Ioannis
RADIOGRAPHICS, 2022, 42 (07) : 1956 - 1974
[44] Mathematical prediction of clinical outcomes in advanced cancer patients treated with checkpoint inhibitor immunotherapy
Butner, Joseph D.
Elganainy, Dalia
Wang, Charles X.
Wang, Zhihui
Chen, Shu-Hsia
Esnaola, Nestor F.
Pasqualini, Renata
Arap, Wadih
Hong, David S.
Welsh, James
Koay, Eugene J.
Cristini, Vittorio
SCIENCE ADVANCES, 2020, 6 (18):
[45] Radiomics-guided checkpoint inhibitor immunotherapy for precision medicine in cancer: A review for clinicians
Zhou, Huijie
Luo, Qian
Wu, Wanchun
Li, Na
Yang, Chunli
Zou, Liqun
FRONTIERS IN IMMUNOLOGY, 2023, 14
[46] Circulating tumor DNA (ctDNA) dynamics in response to checkpoint inhibitor immunotherapy in colorectal cancer
Patell, Kanchi
Kurian, Matthew
Booker, Benjamin
Chung, Michelle
Bennett, Alexis
Bajor, David L.
Mohamed, A. M. R.
Mahipal, Amit
Chakrabarti, Sakti
Selfridge, J. Eva
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[47] Current Status and Future Perspectives of Checkpoint Inhibitor Immunotherapy for Prostate Cancer: A Comprehensive Review
Kim, Tae Jin
Koo, Kyo Chul
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (15) : 1 - 16
[48] Risk Factors for Immune Checkpoint Inhibitor Immunotherapy Toxicity Among Older Adults with Cancer
Johns, Andrew C.
Yang, Mike
Wei, Lai
Grogan, Madison
Spakowicz, Daniel
Patel, Sandipkumar H.
Li, Mingjia
Husain, Marium
Kendra, Kari L.
Otterson, Gregory A.
Rosko, Ashley E.
Andersen, Barbara L.
Carbone, David P.
Owen, Dwight H.
Presley, Carolyn J.
ONCOLOGIST, 2023, : E625 - E632
[49] Looking Beyond Checkpoint Inhibitor Monotherapy: Uncovering New Frontiers for Pancreatic Cancer Immunotherapy
Giurini, Eileena F.
Ralph, Oliver
Pappas, Sam G.
Gupta, Kajal H.
MOLECULAR CANCER THERAPEUTICS, 2025, 24 (01) : 18 - 32
[50] EFFICACY OF CHECKPOINT INHIBITOR IMMUNOTHERAPY DRUG PEMBROLIZUMAB (KEYTRUDA) FOR TREATMENT OF ADVANCED CERVICAL CANCER
Ahmed, F.
Shah, Z.
Khan, I.
Bhatnagar, A.
Garimella, R.
Mishra, S.
Gudapati, S.
Bobba, S. H.
Zaidi, S.
Andrews, K.
Salman, U.
Yukselen, Z.
Guntipalli, P.
Zarrar, R.
Nya, G. Enebong
Ahmad, S.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2021, 31 : A32 - A32

← 1 2 3 4 5 →